Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...

Viridian's thyroid eye disease drug veligrotug clears its first phase 3 trial, with data suggesting it could be competitive with Amgen's Tepezza.

Viridian Therapeutics has a couple of milestones upcoming in 2025 and more pivotal once scheduled in 2026. Click here to find out why VRDN stock is a Buy.

I got to test Viridian Weapon Technologies’ RFX45 Closed Emitter Green Dot Reflex Sight, which I saw for the first time during SHOT 2023.Unlike conventional LED optics, the RFX45 uses a green ...

Viridian said this week that it is on track to report the phase 3 results from REVEAL-1 and REVEAL-2 trials of VRDN-003 in active and chronic TED patients in the first half of 2026, and I believe ...

Viridian has reintroduced its entire C Series of pistol-mounted green laser sights and lights, and—as the only SKU incorporating each of these elements—the C5L represents the lineup’s most ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in ...

Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2 ...